A phase I trial of perillyl alcohol in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Monoterpenes
  • Neoplasms

abstract

  • The MTD of perillyl alcohol for this schedule was determined to be 8400 mg/m(2) per day. This is higher than the MTDs determined in other similar phase I trials. This may have been due to the fact that the gastrointestinal symptoms caused by perillyl alcohol are highly subjective, with high interpatient variability. Phase II trials of perillyl alcohol in hormone-refractory prostate, breast, ovarian and colorectal cancer using doses in the range 4800-6400 mg/m(2) per day are underway.

publication date

  • June 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 12695855

Additional Document Info

start page

  • 493

end page

  • 8

volume

  • 51

number

  • 6